Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1371/journal.pone.0162199 http://scihub22266oqcxt.onion/10.1371/journal.pone.0162199 C5017617!5017617 !27611077     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27611077 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27611077 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       PLoS+One 2016 ; 11 (9 ): e0162199 Nephropedia Template TP {{tp|p=27611077 |t=2016. Experimental Treatment of Ebola Virus Disease with Brincidofovir |pdf=|usr=}}{{27611077 }} gab.com Text Experimental Treatment of Ebola Virus Disease with Brincidofovir JO: PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=27611077 #FOAvip BACKGROUND: The nucleotide analogue brincidofovir was developed to prevent and treat infections caused by double-stranded DNA viruses. Based on in vitro data suggesting an antiviral effect against Ebola virus, brincidofovir was included in the World Health Organisation list of agents that should be prioritised for clinical evaluation in patients with Ebola virus disease (EVD) during the West African epidemic. METHODS AND FINDINGS: In this single-arm phase 2 trial conducted in Liberia, patients with laboratory-confirmed EVD (two months of age or older, enrolment bodyweight ?50 kg) received oral brincidofovir 200 mg as a loading dose on day 0, followed by 100 mg brincidofovir on days 3, 7, 10, and 14. Bodyweight-adjusted dosing was used for patients weighing <50 kg at enrolment. The primary outcome was survival at Day 14 after the first dose of brincidofovir. Four patients were enrolled between 01 January 2015 and 31 January 2015. The trial was stopped following the decision by the manufacturer to terminate their program of development of brincidofovir for EVD. No Serious Adverse Reactions or Suspected Unexpected Serious Adverse Reactions were identified. All enrolled subjects died of an illness consistent with EVD. CONCLUSIONS: Due to the small sample size it was not possible to determine the efficacy of brincidofovir for the treatment of EVD. The premature termination of the trial highlights the need to establish better practices for preclinical in-vitro and animal screening of therapeutics for potentially emerging epidemic infectious diseases prior to their use in patients. TRIAL REGISTRATION: Pan African Clinical Trials Registry PACTR201411000939962. Twit Text FOAVip Experimental Treatment of Ebola Virus Disease with Brincidofovir ????PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=27611077 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27611077 #FOAvip English Wikipedia <ref>{{Cite pmid|27611077 }}</ref> Experimental Treatment of Ebola Virus Disease with Brincidofovir #MMPMID27611077 Dunning J ; Kennedy SB ; Antierens A ; Whitehead J ; Ciglenecki I ; Carson G ; Kanapathipillai R ; Castle L ; Howell-Jones R ; Pardinaz-Solis R ; Grove J ; Scott J ; Lang T ; Olliaro P ; Horby PW PLoS One 2016[]; 11 (9 ): e0162199 PMID27611077 show ga BACKGROUND: The nucleotide analogue brincidofovir was developed to prevent and treat infections caused by double-stranded DNA viruses. Based on in vitro data suggesting an antiviral effect against Ebola virus, brincidofovir was included in the World Health Organisation list of agents that should be prioritised for clinical evaluation in patients with Ebola virus disease (EVD) during the West African epidemic. METHODS AND FINDINGS: In this single-arm phase 2 trial conducted in Liberia, patients with laboratory-confirmed EVD (two months of age or older, enrolment bodyweight ?50 kg) received oral brincidofovir 200 mg as a loading dose on day 0, followed by 100 mg brincidofovir on days 3, 7, 10, and 14. Bodyweight-adjusted dosing was used for patients weighing <50 kg at enrolment. The primary outcome was survival at Day 14 after the first dose of brincidofovir. Four patients were enrolled between 01 January 2015 and 31 January 2015. The trial was stopped following the decision by the manufacturer to terminate their program of development of brincidofovir for EVD. No Serious Adverse Reactions or Suspected Unexpected Serious Adverse Reactions were identified. All enrolled subjects died of an illness consistent with EVD. CONCLUSIONS: Due to the small sample size it was not possible to determine the efficacy of brincidofovir for the treatment of EVD. The premature termination of the trial highlights the need to establish better practices for preclinical in-vitro and animal screening of therapeutics for potentially emerging epidemic infectious diseases prior to their use in patients. TRIAL REGISTRATION: Pan African Clinical Trials Registry PACTR201411000939962. |Adult [MESH] |Antiviral Agents/pharmacology/*therapeutic use [MESH] |Cytosine/*analogs & derivatives/pharmacology/therapeutic use [MESH] |Ebolavirus/drug effects/*physiology [MESH] |Female [MESH] |Hemorrhagic Fever, Ebola/*drug therapy/virology [MESH] |Humans [MESH] |Liberia [MESH] |Male [MESH] |Middle Aged [MESH] |Organophosphonates/pharmacology/*therapeutic use [MESH] |Treatment Outcome [MESH]Experimental Treatment of Ebola Virus Disease with Brincidofovir (epmc).pdf DeepDyve Pubget Overpricing